WARNING: We do not support Internet Explorer. It is not secure and will not work correctly. Please come back using a newer web browser.
Find important updates, industry news, and information on CLSI’s upcoming events. Check out past CLSI press releases, upcoming Committees Week, and newsworthy items.
August 3, 2023
Clinical and Laboratory Standards Institute (CLSI) is pleased to announce that it has been awarded a Power of Associations Gold Award from the American Society of Association Executives (ASAE) for CLSI’s successful global #MicroFree program.
Read MoreMarch 31, 2023
The Clinical and Laboratory Standards Institute (CLSI) has published M24S—Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes, 2nd Edition. M24S includes the minimal inhibitory concentrations and QC ranges developed following the standards described in CLSI document M24, which includes susceptibility testing procedures for Mycobacterium tuberculosis complex (MTBC), clinically significant slowly and rapidly growing mycobacterial species, Nocardia spp., and other aerobic actinomycetes. Also included in this standard are recommendations for selecting agents for first-line and second-line drug testing, organism group–specific methodologies, reporting recommendations, and organism quality control criteria.
Read MoreMarch 3, 2023
CLSI has published M100—Performance Standards for Antimicrobial Susceptibility Testing, 33rd Edition. The tables presented in M100 represent the most current information for drug selection, interpretation, and quality control using the procedures standardized in CLSI documents M02, M07, and M11. This document is intended for use by microbiology labs, antimicrobial stewardship teams, infectious disease experts, and other relevant stakeholders intending to provide optimal patent care using the most up-to-date antimicrobial susceptibility breakpoints and test methods. To ensure the correct use of the document, users should replace previously published tables with the new edition immediately.
Read MoreJanuary 30, 2023
The Clinical and Laboratory Standards Institute announces the recipients of its 2023 Excellence Awards. These awards celebrate the achievements of CLSI volunteers and organizational members who are committed to CLSI’s mission and have helped improve the quality of medical care worldwide. Recipients are recognized for dedicating significant time and effort to the development, implementation, and promotion of CLSI standards.
Read More
October 28, 2022
The Clinical and Laboratory Standards Institute (CLSI) has published the 3rd Edition of EP19—A Framework for Using CLSI Documents to Evaluate Medical Laboratory Test Methods. The 3rd Edition of the EP19 Report is available free, and introduces the Test Life Phases Model, which points users to CLSI evaluation protocol documents to establish and implement commercially manufactured or laboratory-developed test (LDT) methods.
Read More
October 21, 2022
The Clinical and Laboratory Standards Institute (CLSI) has announced that a new and updated version of the I/LA37 Database, Supplemental Data for Allergen Specificity for IgE Antibody Autoanalyzers, is now available. The updated database provides essential allergen information for allergy testing manufacturers and hospitals performing allergy testing, both laboratories and clinicians. It includes a harmonized listing of the allergen codes currently used by immunoglobulin E antibody assay manufacturers, along with their common name, Latin name, and allergen grouping.
Read More
September 12, 2022
The Clinical and Laboratory Standards Institute (CLSI) announces that the Pan American Health Organization (PAHO) Member States have admitted CLSI into official relations as a non-state actor with PAHO for a period of three years (2022-2024). PAHO acts as the Regional Office for the Americas of the World Health Organization (WHO).
Read More
August 24, 2022
The Clinical and Laboratory Standards Institute (CLSI) has announced the publication of three new editions of antifungal documents: M57S—Epidemiological Cutoff Values for Antifungal Susceptibility Testing, 4th Edition, M27M44S—Performance Standards for Antifungal Susceptibility Testing of Yeasts, 3rd Edition, and M38M51S—Performance Standards for Antifungal Susceptibility Testing of Filamentous Fungi, 3rd Edition.
Read More
July 27, 2022
The Clinical and Laboratory Standards Institute has published the 4th Edition of EP14—Evaluation of Commutability of Processed Samples.
Read More
June 16, 2022
The Clinical and Laboratory Standards Institute (CLSI) has published the second edition of QMS15—Laboratory Internal Audit Program. This guideline provides recommendations for establishing an internal audit program and related processes for enhanced quality and continual improvement in the laboratory.
Read More